Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

<p>CONSORT Diagram</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Aurelius Omlin (14971513) (author)
Tác giả khác:	Richard Cathomas (14971516) (author), Gunhild von Amsberg (14971519) (author), Christoph Reuter (14971522) (author), Susan Feyerabend (14971525) (author), Wolfgang Loidl (14971528) (author), Martin Boegemann (14971531) (author), Anja Lorch (14971534) (author), Axel Heidenreich (14971537) (author), Igor Tsaur (14971540) (author), Julian Larcher-Senn (14971543) (author), Stefan A.J. Buck (14971546) (author), Ron H.J. Mathijssen (14971549) (author), Ulrich Jaehde (14971552) (author), Silke Gillessen (14971555) (author), Markus Joerger (14971558) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Chemotherapy Clinical-Stage Research Computational Methods Algorithms Genitourinary Cancers Prostate cancer Pharmacology Pharmacokinetics and pharmacodynamics
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Bằng: Aurelius Omlin (14971513)
Được phát hành: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Bằng: Evan C. Chen (15054014)
Được phát hành: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Bằng: Evan C. Chen (15054014)
Được phát hành: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Bằng: Evan C. Chen (15054014)
Được phát hành: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Bằng: Evan C. Chen (15054014)
Được phát hành: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Bằng: Evan C. Chen (15054014)
Được phát hành: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Bằng: Evan C. Chen (15054014)
Được phát hành: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Data Sheet 1_Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.docx
Bằng: Yajie He (20323682)
Được phát hành: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Bằng: Yan Zhou (15053225)
Được phát hành: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Bằng: Chong Kin Liam (15331321)
Được phát hành: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Bằng: Chong Kin Liam (15331321)
Được phát hành: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Bằng: Chong Kin Liam (15331321)
Được phát hành: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Bằng: Chong Kin Liam (15331321)
Được phát hành: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Bằng: Zev A. Wainberg (15047031)
Được phát hành: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Bằng: Elizabeth R. Tucker (15053624)
Được phát hành: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Bằng: Elizabeth R. Tucker (15053624)
Được phát hành: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Bằng: Elizabeth R. Tucker (15053624)
Được phát hành: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Bằng: Elizabeth R. Tucker (15053624)
Được phát hành: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Bằng: Elizabeth R. Tucker (15053624)
Được phát hành: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Bằng: Elizabeth R. Tucker (15053624)
Được phát hành: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Bằng: Michelle L. Mierzwa (14963463)
Được phát hành: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Bằng: Arun Kanakkanthara (14937731)
Được phát hành: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Bằng: Arun Kanakkanthara (14937731)
Được phát hành: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Bằng: Alyssa C. Flint (16676029)
Được phát hành: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Bằng: Alyssa C. Flint (16676029)
Được phát hành: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Bằng: Sanna Pikkusaari (15055802)
Được phát hành: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Bằng: Sanna Pikkusaari (15055802)
Được phát hành: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Bằng: Gregory L. Beatty (15087193)
Được phát hành: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Bằng: Gregory L. Beatty (15087193)
Được phát hành: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Bằng: Zachary Quinn (15052893)
Được phát hành: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Bằng: Fabrice Barlesi (15045504)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_fs12svc4s2lnasltqfedsce52t